The prevalence of heart failure in patients with diabetes is four times higher than in the general population. Likewise, chronic kidney disease (CKD) and diabetes are common morbidities. As new drug classes emerge in the management of diabetes and heart failure and CKD, it is important to thoroughly evaluate available literature and identify opportunities to reduce complications and costs. Sotagliflozin is a first-in-class dual SGLT-1 and 2 inhibitor approved in Europe. Does it improve outcomes in patients with heart failure or CKD?
Guest Authors: Maren Richards Brinton, PharmD and Jonathan C. Hughes, PharmD, BCPS, BCACP
Music by Good Talk
Intensive Antiplatelet Therapy - Is Extended Therapy Worth It?
Co-trimoxazole+RAAS Inhibitors: A Deadly Combination?
Anticoagulation Bridge Therapy - Risks and Benefits Examined
Fish Oil for Rheumatoid Arthritis
Home-Based Primary Care: Can We Take These Results to the Bank?
Community Health Workers to Improve Asthma Outcomes
Potential Uses of Niacin: Flushing Out The Results of HPS2-THRIVE
Create your
podcast in
minutes
It is Free
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive